Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines to send his nomination to the full chamber.

Oprah Winfrey is sharing new details on her weight loss in recent years ... they feel full sooner. Wegovy and Zepbound are approved by the U.S. Food and Drug Administration for people with ...

Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's (LLY) tirzepatide, which is marketed for diabetes as Mounjaro and for weight loss as Zepbound.

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co ... Retatrutide has been shown to produce the greatest weight loss of any GLP-1. With the popularity ...

In a study of Eli Lilly’s Zepbound, weight loss increased (PDF) from 20.9% after 36 weeks to 25.8% after 88 weeks. The top-line data shared by Novo Friday lack important details, including ...

Lilly’s weekly Zepbound is the frontrunner among obesity treatments on the market — helping patients lose an average of 20.2% of their body weight over a 72-week period. However, by comparison, ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.